Gadofosveset
As of the edition of 20 October 2026, Gadofosveset is a small molecule: marketed, first approved in 2008 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Ablavar
- First approved
- 22 December 2008 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Lantheus Medical Imaging
- Withdrawn from market
- 18 October 2011 (in some regions)
- Registered trials
- 12, 2 stopped early
- Disease areas
- Cancer; Heart and blood vessels; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 5 | 0 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 0 | 0 | 1 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lantheus Medical Imaging | Acquired holder and Lead sponsor of trials | 2009 to now |
| Epix Pharmaceuticals | Originator | 2008 to 2009 |